Dr. Christiane Reitz's lab focuses on understanding the genetic factors contributing to neuropsychiatric symptoms in Alzheimer's disease, particularly in diverse populations such as Hispanic and African-American individuals. They aim to create a large, harmonized dataset that includes genetic, neuroanatomical, and clinical data to better understand how ancestry influences these symptoms and to ultimately inform better treatment options. This research is crucial as it endeavors to address historical gaps in Alzheimer's research and improve outcomes for affected populations.

Dr. Nim Tottenham's lab focuses on understanding how adolescents in low- and middle-income countries overcome early adversities to develop resilient emotion regulation skills. By using advanced brain imaging and behavioral assessments, the research aims to identify the protective factors that help youth cope with adversity. This research is particularly important because it addresses a critical gap in knowledge about resilience in populations often overlooked in scientific studies.

Dr. Tomislav Rovis' lab focuses on innovative methods to transform basic chemical feedstocks into valuable compounds, especially those containing nitrogen, which is crucial for drug development. By synthesizing complex structures from simple molecules, the lab aims to streamline the creation of pharmaceutical agents and improve their properties. This research has a significant impact on drug design and functionality, addressing challenges in the development of therapeutics.

Dr. Sergei Doulatov's lab focuses on understanding how mutations in the SF3B1 gene affect hematopoietic stem cells, which are crucial for blood production. By exploring how these mutations alter RNA splicing, the lab aims to uncover their role in diseases like myelodysplastic syndromes (MDS). Ultimately, the research seeks to develop new treatment strategies targeting these mutations to improve patient outcomes.

Dr. Daphna Shohamy's lab at Columbia University studies how the human brain learns to recognize patterns and generalize knowledge from past experiences. The research focuses on the cognitive process of abstraction, which allows individuals to simplify complex information by identifying shared features across experiences. By using brain imaging techniques, the lab explores how motivational states affect learning and decision-making, particularly in the context of emotional responses and psychiatric disorders.

Dr. Samuel K Sia's lab focuses on creating innovative diagnostic tools that are both environmentally friendly and efficient. One of their key projects involves developing biodegradable materials for microfluidic devices, which can help reduce waste in medical testing. Another major aim is to create a rapid and user-friendly test for hepatitis C that combines sample preparation and testing into one quick process, making it easier for patients to get diagnosed and treated in a single visit.

Dr. Steven Siegelbaum's lab at Columbia University focuses on understanding how the brain processes social memories, specifically through the hippocampus and its CA2 region. The research explores how the brain distinguishes between rewarding and threatening social interactions, which is crucial for social functioning. By using animal models, the lab aims to uncover the neural circuits involved in memory and social behavior, and how alterations in these circuits may be linked to conditions like anxiety and schizophrenia.

Dr. Yaakov Stern's lab at Columbia University focuses on understanding the relationship between cognitive aging and Alzheimer’s disease (AD). The team uses advanced imaging techniques to explore how neural networks associated with memory and other cognitive abilities change with age and how modern family and work life impacts the risk of developing Alzheimer's disease. By studying diverse populations, they aim to identify key factors that could help prevent cognitive decline in older adults.

Dr. Virginia W. Cornish's lab at Columbia University focuses on developing innovative therapeutic approaches using engineered yeast. They are creating living yeast cells that can act as biosensors to detect infections and secrete antibiotics directly where needed, like in wound care. This research aims to improve treatment strategies for various diseases by utilizing synthetic biology techniques to manipulate yeast at the genome level.

Dr. Catarina M. Quinzii's lab at Columbia University focuses on understanding the molecular mechanisms behind frontotemporal dementia (FTD) caused by abnormal Tau protein. The lab investigates how a process called SUMOylation influences Tau behavior and its impact on brain function, specifically regarding mitochondria and synapses. By using animal models and cell lines derived from patients, the team aims to identify potential therapeutic strategies to improve cognitive functions in FTD.

Dr. Giuseppe Tosto's lab at Columbia University focuses on understanding Alzheimer's disease, particularly within Hispanic/Latino populations. Acknowledging that these groups have a higher prevalence of Alzheimer's, the lab aims to enhance genetic research by sequencing the genomes of 6,000 individuals from diverse Hispanic backgrounds, especially those with significant Native American ancestry. This work will help in uncovering rare genetic variants associated with the disease and improving our understanding of Alzheimer's in underrepresented populations.

Dr. Osama Al Dalahmah's lab at Columbia University focuses on understanding the role of astrocytes, a type of brain cell, in Alzheimer's disease. They are particularly interested in a protein called CD44 that is expressed in these cells and how it may influence the progression of the disease. The lab uses various experimental techniques to study astrocytes in both lab settings and animal models to identify potential new treatments for Alzheimer's.

Dr. Ai Yamamoto's lab at Columbia University focuses on understanding and addressing neurodegenerative diseases such as Parkinson's and Alzheimer's. The research primarily investigates the role of autophagy, a key cellular process that cleans out damaged components in neurons, and how its dysfunction contributes to these diseases. By examining specific cellular pathways, including calcium signaling and the role of certain proteins, the lab aims to identify potential therapeutic targets to treat these debilitating conditions.

Tal Danino's research lab focuses on developing innovative bacterial therapies to enhance cancer treatments, particularly for triple-negative breast cancer. By engineering probiotic bacteria to deliver therapeutics directly to tumors, the lab aims to overcome the limitations of traditional immunotherapy, offering safer and more effective options for patients. They utilize advanced synthetic biology techniques to create systems that allow these bacteria to selectively release drugs at the tumor site.

Dr. Soojin Park's lab at Columbia University Health Sciences focuses on improving the management of patients suffering from acute hydrocephalus and delayed cerebral ischemia, particularly after brain injuries like subarachnoid hemorrhages. The lab leverages machine learning and artificial intelligence to develop predictive models that help identify complications early, aiming to reduce hospital stays and improve patient outcomes. Research utilizes data from patient monitoring to enhance decision-making processes in critical care settings.

Arthur G. Palmer's lab focuses on understanding how the shapes of proteins and their movements influence their functions in biological processes. They study conformational changes in proteins—like how they fold or interact with other molecules—using advanced techniques such as NMR spectroscopy and molecular dynamics simulations. Their research has implications for various diseases and can aid in the design of new therapeutic agents.

Dr. C. Daniel Salzman's lab at Columbia University focuses on understanding how the brain makes decisions and processes social information. They explore neural mechanisms involved in decision-making, especially in novel situations and when responding to social cues, using techniques like electrophysiology and behavioral assays. Research from this lab aims to shed light on the complexities of motivated behavior and emotional regulation, particularly in the context of psychiatric disorders.

Dr. Stavroula Kousteni's lab at Columbia University Health Sciences focuses on understanding the molecular and epigenetic changes in hematopoietic stem cells (HSCs) that contribute to diseases like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) as patients age. They investigate how factors such as mutations, inflammation, and changes in the bone marrow microenvironment influence the evolution of these blood disorders. The lab aims to uncover potential therapeutic targets for improving treatments or preventing the progression of these conditions.

Dr. Steven L. Reiner's lab at Columbia University focuses on understanding how to improve cancer immunotherapy, which harnesses the body's immune system to fight cancers. The lab is investigating mechanisms of T cell behavior in response to cancers and how to enhance their ability to persist and effectively attack tumors. Ultimately, their work aims to develop better predictive tests for treatment response and advanced strategies for patients who do not respond well to current therapies.

Dr. X. Shawn Liu's lab at Columbia University focuses on developing innovative therapies for Rett syndrome, a severe neurodevelopmental disorder primarily affecting girls. The lab's research aims to reactivate the MECP2 gene from a silenced X chromosome, which offers a potential treatment by restoring function in neurons. They utilize advanced mouse models and genetic editing tools to explore this groundbreaking approach, with hopes of leading to future clinical trials.